Furthermore, EGFR inhibitors may provide an advantage in highly heterogeneous gastric adenocarcinomas by acting both on cells susceptible to the action on EGFR and cells sensitive to the off-target activity on ABCG2. The gene discussed is EGFR; the disease is gastric adenocarcinoma.